A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

NCT03761407 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Pain

Interventions

DRUG: 100 mg GRT0151Y
DRUG: 125 mg GRT0151Y
DRUG: 150 mg GRT0151Y
DRUG: 225 mg GRT0151Y
DRUG: Matching placebo

Sponsor

Grünenthal GmbH